
Your Feed
Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD | #ASH24
Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD | #ASH24
ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24
Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24
Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24
Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24
Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24



